Seeking AlphaCodex · 实盘不做把握 6/10
北京时间·🕒 发布 01:32:37时区推断·⟳ 抓取 01:34:10·⚡ 决策 07-24 01:35:58 +1m48s·95.8 天前
FDA顾问小组支持将BPC-157纳入503A复方药物清单，Hims & Hers盘中大涨
FDA顾问小组以8-6支持BPC-157相关形式进入503A Bulks List，若FDA最终采纳，将扩大复方药房合法制备相关肽类产品的空间。
📄 原文Seeking Alpha↗ 原文
Hims & Hers gains as FDA panel endorses peptide BPC-157
Shares of Hims & Hers Health (HIMS) rose more than 10% on Thursday after an FDA advisory panel voted to include a popul…
不做 Hims & Hers Health（HIMS.US）
事件方向利多但只是FDA顾问小组非约束性投票，正式监管落地仍未确认；会前预期已有传播且信号到达时HIMS已盘中涨超10%，追多缺少足够剩余edge，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- FDA会前背景文件已披露并建议反对将七种肽类加入503A清单，说明会议和监管分歧并非突发。
- FDA官方会议日程确认7月23日讨论BPC-157、KPV、TB-500和MOTs-C等是否纳入503A Bulks List。
- Seeking Alpha报道顾问小组8-6支持BPC-157 free base和acetate进入503A清单，并点名HIMS盘中涨超10%。市场反应:HIMS盘中已涨超10%。
- MarketWatch确认顾问投票支持BPC-157复方使用，但强调这并不等同于FDA正式批准。
关键理由
- FDA顾问小组以8-6支持BPC-157相关形式进入503A Bulks List，若FDA最终采纳，将扩大复方药房合法制备相关肽类产品的空间。
- Hims & Hers已布局肽类产能，Leerink称其有望取得2027年约22亿美元远程医疗肽类市场约20%份额，理论可触达约4.4亿美元收入机会，相对其约23.7亿美元TTM收入有一定增量弹性。
- 但本次只是非约束性顾问投票，FDA最终决定和商业化节奏仍未落地，且信号到达时HIMS已因该消息盘中上涨超过10%。
主要风险
- FDA正式规则仍可能不采纳顾问建议，且FDA背景文件此前对多种肽类的安全性和证据充分性持保留态度。
- 会议日程和肽类放松预期已在会前多日被行业媒体和主流媒体讨论，盘中超过10%的即时涨幅使追高性价比不足。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-21 · 影响 weakens
FDA背景文件此前建议反对加入503A清单，削弱顾问投票直接转化为确定商业化利好的强度。
检索:FDA briefing documents recommend against BPC-157 503A Bulks List July 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-23 · 影响 supports
公开报道支持HIMS具备肽类业务敞口，但同时显示市场已在消息发布时快速上调价格。
检索:Hims Hers peptide facility BPC-157 telehealth peptide market Leerink 2027 原文 ↗
原文全文
展开原文 · 1,118 字
Shares of Hims & Hers Health (HIMS) rose more than 10% on Thursday after an FDA advisory panel voted to include a popular peptide known as BPC-157 in a list of molecules that compounding pharmacies use to make customized treatments.
The FDA’s pharmacy compounding advisory committee voted 8–6 to place BPC-157 free base form on the agency’s 503A Bulks List and voted 8–6 with one abstention to place BPC-157 Acetate form on the same list.
Compounding pharmacies are allowed to use constituents of the 503A Bulks List for the production of customized treatments.
The voting comes on the first day of a two-day meeting scheduled to discuss seven peptide products that the agency removed in 2023 from the list.
The FDA's advisory committees issue non-binding recommendations. However, the regulator usually follows them before making a final decision on authorizations.
Hims & Hers Health (HIMS), which markets compounding drugs, acquired a peptide facility in California last year. The company is poised to capture a fifth of the telehealth peptide market, expected to reach $2.2B in 2027, according to Leerink Partners.
The FDA’s pharmacy compounding advisory committee voted 8–6 to place BPC-157 free base form on the agency’s 503A Bulks List and voted 8–6 with one abstention to place BPC-157 Acetate form on the same list.
Compounding pharmacies are allowed to use constituents of the 503A Bulks List for the production of customized treatments.
The voting comes on the first day of a two-day meeting scheduled to discuss seven peptide products that the agency removed in 2023 from the list.
The FDA's advisory committees issue non-binding recommendations. However, the regulator usually follows them before making a final decision on authorizations.
Hims & Hers Health (HIMS), which markets compounding drugs, acquired a peptide facility in California last year. The company is poised to capture a fifth of the telehealth peptide market, expected to reach $2.2B in 2027, according to Leerink Partners.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。